A phase I clinical trial to evaluate the safety and immunogenicity of pGA2/JS7 DNA vaccine and recombinant modified vaccinia Ankara/HIV62 vaccine in healthy, HIV-1-uninfected adult participants.

Trial Profile

A phase I clinical trial to evaluate the safety and immunogenicity of pGA2/JS7 DNA vaccine and recombinant modified vaccinia Ankara/HIV62 vaccine in healthy, HIV-1-uninfected adult participants.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2015

At a glance

  • Drugs MVA-HIV62 (Primary) ; PGA2-JS7 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 26 Mar 2012 Actual end date Dec 2008 added as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Results reported in the Journal of Infectious Diseases, according to a GeoVax Labs media release.
    • 18 Feb 2008 Results from Part 1 presented at the 15th Conference on Retroviruses and Opportunistic Infections (CROI).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top